SCHEMBL19664446

SCHEMBL19664446

Cn1c(CCl)nc2cc(C(F)(F)F)ccc21

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 7/20 0.53
CNR2 P34972 6/20 0.48
CNR1 P21554 1/20 0.48
DRD4 P21917 5/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
DRD2 P14416 3/20 0.42
PKM P14618 1/20 0.42
HTR3E A5X5Y0 1/20 0.41
KDM4E B2RXH2 1/20 0.41
HTR3B O95264 1/20 0.41
TP53 P04637 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
HTR1A P08908 1/20 0.41
CYP2D6 P10635 1/20 0.41
TSHR P16473 1/20 0.41
NFKB1 P19838 1/20 0.41
HTR1D P28221 1/20 0.41
HTR2C P28335 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16256875 0.86 GRM2 (0.51) GRM2CNR2CNR1DRD4MEN1
SCHEMBL13603591 0.85 GRM2 (0.50) GRM2CNR2CNR1DRD4MEN1
SCHEMBL11955035 0.84 GRM2 (0.49) GRM2CNR2CNR1DRD4MEN1
SCHEMBL20001367 0.84 CNR2 (0.50) GRM2CNR2CNR1DRD4MEN1
SCHEMBL18090934 0.82 GRM2 (0.48) GRM2CNR2CNR1DRD4MEN1
SCHEMBL1748120 0.80 SMN1; SMN2 (0.53) GRM2CNR2CNR1MEN1KMT2A
SCHEMBL103416 0.80 PIK3CD (0.47) GRM2MEN1KMT2APKM
SCHEMBL8058929 0.78 KDM4E (0.50) GRM2MEN1KMT2APKMHTR3E
SCHEMBL10238327 0.78 MEN1 (0.47) GRM2CNR2CNR1MEN1KMT2A
SCHEMBL4159853 0.78 KMT2A (0.49) GRM2DRD4KMT2AKDM4ETP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4638436-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. (US) 2025-10-29 EP disclosed
US-20240254118-A1 PRMT5 INHIBITORS AND USES THEREOF GILEAD SCIENCES, INC. 2024-08-01 US disclosed
EP-2914597-B1 PYRAZOLOPYRIDINE DERIVATIVES AS TTX-S BLOCKERS RAQUALIA PHARMA INC (JP) 2017-12-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240254118-A1 PRMT5 INHIBITORS AND USES THEREOF PRMT5, PRMT1, PRMT9 GRM2 2058/4885CNR2 4788/4885CNR1 4775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.